We are conducting routine maintenance on portfolio manager. We'll be back up as soon as possible. Thanks for your patience.

TOP NEWS: AstraZeneca hails recommended EU approval of Tagrisso

(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products ...

Alliance News 18 November, 2024 | 9:01AM
Email Form Facebook Twitter LinkedIn RSS

(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso as treatment for a form of lung cancer.

The Cambridge, England-based pharmaceutical company said the recommended approval is for adults with locally advanced, unresectable non-small cell lung cancer whose tumours have epidermal growth factor receptor exon 19 deletions or exon 21 substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.

The recommendation is based on results from the Laura phase 3 trial which showed Tagrisso reduced the risk of disease progression or death by 84% compared to placebo.

Median progression-free survival was 39.1 months in patients treated with Tagrisso compared to 5.6 months for placebo.

"Today's news reinforces Tagrisso as the backbone therapy in EGFR-mutated non-small cell lung cancer, meeting the critical unmet need for an effective targeted treatment option in the unresectable setting. Tagrisso has now demonstrated its benefit across all stages of EGFR-mutated lung cancer, representing a pivotal step in transforming care for patients who are urgently in need of innovative therapies that can help extend their lives," said Susan Galbraith, executive vice president, Oncology research & development at AstraZeneca.

Tagrisso is currently approved as monotherapy in over 100 countries for several forms of non-small cell lung cancer.

AstraZeneca shares were 0.8% lower at 9,900.73 pence each on Monday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
AstraZeneca PLC 9,893.00 GBX -0.85

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures